Laboratory for Antimicrobial Dynamics, NYS Center of Excellence in Bioinformatics and Life Sciences, Buffalo, New York, USA.
School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02414-20.
We sought to determine if is capable of altering the pharmacodynamics of an antistaphylococcal β-lactam. Two strains of methicillin-susceptible (MSSA) and two isolates were studied in 24-h static time-killing experiments under monoculture or coculture conditions. Bacterial killing of meropenem was described using an empirical pharmacokinetics/pharmacodynamics model that was developed using Hill functions. A mechanism-based pharmacodynamic model was also used to describe the effect of meropenem on each species of bacterium, interspecies interactions, and strain-based covariate effects. Monte Carlo simulations of bacterial killing effects were generated based on the population pharmacokinetics of meropenem in 2,500 simulated critically ill subjects over 48 h. Against one of the two MSSA isolates, the magnitude of bacterial killing () decreased from -4.61 (95% confidence interval [CI], -5.85 to -3.38) to -2.23 (95% CI, -2.85 to -1.61) when cultured in the presence of carbapenem-resistant (CRAB). Similarly, the data were best described by a mechanism-based model where the number of cells produced a systematic increase in the concentration for a 50% maximum killing effect (KC) of 3.53-fold, thereby decreasing MSSA sensitivity to meropenem. A covariate effect by the CRAB isolate resulted in a more pronounced increase in the MSSA KC for meropenem (31.8-fold increase). However, Monte Carlo simulations demonstrated that a high-intensity meropenem regimen is capable of sustained killing against both MSSA isolates despite protection from Thus, and MSSA engage in complex interactions during β-lactam exposure, but optimal antimicrobial dosing is likely capable of killing MSSA despite the potentially beneficial interplay with .
我们试图确定 是否能够改变抗葡萄球菌β-内酰胺类药物的药效动力学。在单培养或共培养条件下,对两种耐甲氧西林金黄色葡萄球菌(MSSA)和两种 分离株进行了 24 小时静态时间杀伤实验。使用经验药代动力学/药效动力学模型描述美罗培南的杀菌作用,该模型使用 Hill 函数开发。还使用基于机制的药效动力学模型来描述美罗培南对每种细菌、种间相互作用和基于菌株的协变量效应的影响。基于 48 小时内 2500 名模拟重症患者的美罗培南群体药代动力学,生成了细菌杀伤效果的蒙特卡罗模拟。对于两种 MSSA 分离株中的一种,当在耐碳青霉烯肠杆菌科(CRAB)存在的情况下培养时,细菌杀灭量( )从 -4.61(95%置信区间[CI],-5.85 至-3.38)减少至 -2.23(95%CI,-2.85 至-1.61)。同样,数据最好用基于机制的模型来描述,该模型中 细胞的数量会导致 50%最大杀伤效应(KC)的 浓度呈系统增加,从而使 MSSA 对美罗培南的敏感性降低。CRAB 分离株的协变量效应导致 MSSA 对美罗培南的 KC 更明显增加(增加 31.8 倍)。然而,蒙特卡罗模拟表明,尽管受到 的保护,高强度的美罗培南方案仍能够持续杀灭两种 MSSA 分离株。因此, 在β-内酰胺暴露期间与 MSSA 发生复杂相互作用,但优化的抗菌药物剂量可能能够杀死 MSSA,尽管与 可能存在有益的相互作用。